Sandoz Launches Generic Copaxone On Heels of Teva Patent Ruling

Sandoz wasted no time in launching its generic version of Copaxone in the U.S. after the U.S. Court of Appeals for the Federal Circuit again invalidated Teva’s patent on the blockbuster multiple sclerosis drug.

Sandoz announced the launch of Glatopa (glatiramer acetate) on June 18, the same day the appeals court ruled 2-1 in Teva Pharmaceuticals, et. al. v. Sandoz, Inc. Momenta Pharmaceuticals, et. al., to set aside Teva’s patent claim. The ruling pushed up the release of a generic competitor by just over two months as the last of Teva’s patents is set to expire on Sept. 1.

Sandoz and Momenta Pharmaceuticals, the companies that developed the generic, received FDA approval in April but had to wait for the court ruling before marketing it (Generic Line, April 29).

The ruling reiterates the Federal Circuit’s July 2013 decision overturning a U.S. district court ruling that had upheld Teva’s patent. The case was appealed to the U.S. Supreme Court, which remanded it back to the Federal Circuit in January, saying the appeals court had erred in attempting to do its own research instead of relying on the district court’s ruling to determine the meaning of “molecular weight” (Generic Line, Feb. 4). The Federal Circuit reviewed the case again and concluded the patent was invalid.

Teva’s patent was tied to a method of manufacturing that focused on the drug’s molecular weight, but the Federal Circuit found the claims invalid for indefiniteness. “Teva cannot transform legal analysis about the meaning or significance of the intrinsic evidence into a factual question simply by having an expert testify,” the court writes.

Sandoz’s once daily Glatopa is indicated for the treatment of patients with relapsing forms of MS.

Teva spokeswoman Denise Bradley says the company has planned for market entry of a generic version of Copaxone and expects patients to continue to value the branded drug. — John Bechtel

 

$1,097 $847

Bonus

Subscribe to Generic Line and save $250 off the regular one-year price of $1,097 — plus receive a FREE copy of our webinar, Expediate Your FDA Generic Drug Approval: Deliver Flawless ANDAs the First Time — a $287 Value!

Key Benefits

LINKS TO KEY DOCUMENTS — Each issue provides you with links that support GEN's articles such as FDA guidances, warning letters, rules, full texts of proposed legislation and more.

FDANEWS DRUG DAILY BULLETIN — This daily email brings you important FDA and international regulatory, legislative and business news in the pharmaceutical industry.

ONLINE ACCESS — Consider our newsletter archive your personal library! Search your current issue — and hundreds of past issues — by keyword and relevancy.